Nanyang Biologics Joins Prestigious Johnson & Johnson Innovation JLABS to Accelerate AI-Driven Drug Discovery

Nanyang Biologics becomes a resident company of JLABS, joining a global network dedicated to accelerating life-enhancing health and wellness solutions.

‍

Nanyang Biologics, a leading AI-powered drug discovery startup, is proud to be a resident company of Johnson & Johnson Innovation JLABS @ Shanghai, a premier life science incubator program. With an acceptance rate of less than 10%, JLABS is one of the most prestigious incubators in the pharmaceutical industry. This global network of life science ecosystems brings together startups, researchers, and industry leaders to foster innovation and accelerate the development of groundbreaking medical solutions. This milestone marks a significant step forward for Nanyang Biologics as it continues to advance its mission of revolutionizing drug discovery through AI.

‍

JLABS: A Global Hub for Life Science Innovation

‍

JLABS, a flagship initiative by Johnson & Johnson Innovation, is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

‍

By providing startups with access to capital-efficient resources, including expertise, community, industry connections and entrepreneurial programs, JLABS enables innovators to transform their ideas into real-world solutions. Since its inception, JLABS has supported hundreds of companies, many of which have gone on to achieve significant milestones in drug development, medical devices, and healthcare technologies.

‍

Empowering Innovation with JLABS

‍

As a member of JLABS, Nanyang Biologics gains access to cutting-edge facilities, including fully equipped labs and cutting-edge technology, to accelerate research and development. Joining JLABS also represents an unparalleled opportunity to benefit from mentorship and expertise provided by seasoned professionals in drug discovery, regulatory affairs, and business development. 

‍

The JLABS ecosystem also offers valuable networking opportunities, connecting the company with potential partners, investors, and collaborators. Furthermore, educational programs such as workshops, seminars, and training sessions will enable Nanyang Biologics to stay ahead of industry trends and best practices, ensuring its continued growth and innovation in the field of AI-driven drug discovery.

‍

“Joining JLABS is a pivotal moment for Nanyang Biologics. It not only validates the potential of our DTIGN platform but also provides us with the resources and support needed to scale our innovations” said Giang Nguyen, CTO of Nanyang Biologics. “We are excited to collaborate with JLABS and its network of industry leaders to push the boundaries of AI-driven drug discovery and make a meaningful impact on global healthcare.”

‍

Transforming Drug Discovery Through AI and Collaboration

‍

The pharmaceutical industry faces significant challenges, including rising costs, lengthy development timelines, and high failure rates in clinical trials. Traditional drug discovery methods can take over a decade and cost billions of dollars, with no guarantee of success and up to 90% of potential compounds failing clinical trials due to poor efficacy or side effects. AI-driven approaches, like the DTIGN platform pioneered by Nanyang Biologics, have the potential to disrupt this paradigm by significantly reducing the time and cost of identifying and optimizing drug candidates.

‍

Pharmaceutical companies are already using AI to help speed up the screening process and DTIGN has already achieved a major breakthrough, improving bioactivity prediction accuracy by an impressive 27.03%, a 64-fold increase in hit rate efficiency, and a 68.2% reduction in drug discovery timelines compared to traditional methods, significantly accelerating the development of novel therapeutics. This advancement positions Nanyang Biologics as a frontrunner in the application of AI to drug discovery, and JLABS will provide the ideal environment to further refine and scale the technology.

‍

What’s Next?

‍

Nanyang Biologics is looking for commercial collaborations with pharmaceutical companies that are focused on drug discovery, particularly in cancer and cardiovascular research. Beyond pharmaceuticals, we are looking to collaborate with universities and technological institutes engaged in molecular research. 

‍

These partnerships aim to speed up the discovery of new therapeutic compounds and enhance the precision of drug design, culminating in breakthroughs that could improve patient care. By integrating their AI solutions into academic and institutional settings, Nanyang Biologics can empower research teams to tackle complex scientific challenges.

‍

About Nanyang Biologics

Nanyang Biologics is an AI-driven biotech company dedicated to advancing drug discovery. By combining machine learning, high-performance computing, and pharmaceutical expertise, the company accelerates research in cancer, metabolic disorders, and neurodegenerative diseases. Through strategic partnerships with Johnson & Johnson, Nanyang Biologics continues to push the limits of AI-driven pharmaceutical innovation, optimizing drug development and reducing discovery timelines.